Introduction
Pseudomyxoma peritonei (PMP) is a rare disease with the incidence of 1-2 cases per million per year [ 1, 2] . It is slowly progressive condition that usually arises from perforation of appendix due to an enlarging appendiceal adenoma or carcinoma, allowing mucin producing neoplastic cells to gain access to peritoneal cavity. PMP syndrome rarely metastases outside the abdominal cavity but remains a fatal illness as the space in the abdomen and pelvis required for normal function of the gastrointestinal tract becomes filled with copious amounts of the mucinous tumor [1, 2] . Eventually patients develop terminal starvation because of abdominal distension and increased tumour volume [2] .
Most cases of cystic ovarian mucinous tumors associated with pseudomyxoma peritonei are associated with metastases from an appendiceal tumor [3] . In women, cells become entrapped within the corpus hemorrhagicum and consequently, it is the detection of an ovarian cyst that often brings about the diagnosis of pseudmyxoma peritonei [3] .
The pathologic classification of PMP is controversial SVEIKATOS MOKSLAI / HEALTH SCIENCES IN EASTERN EUROPE ISSN 1392-6373 print / 2335-867X online 2016, 26 tomas, Nr. 5, p. 88-92 DOI: http://doi.org/10.5200/sm-hs.2016.078 BIOMEDICINA / BIOMEDICINE and confusing. In 1995, Ronnett et al described three distinct cathegories of PMP on the basis of pathologic specimens (n=109): diffuse peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and an intermediate/discordant subtype (PMCA-I/D). DPAM originates from an appendiceal mucinous adenoma and produces abundant mucin but minimal mucinous epithelium that lacks significant cytologic atypia and mitoses. The prognosis of DPAM is good. An appendiceal adenocarcinoma causes PMCA, which features more mucinous epithelium and pathology that is typical of adenocarcinoma. The prognosis of PMCA is poor. The third category, PMCA-I/D, has characteristics of both DPAM and PMCA, and the prognosis is intermediate between the two. [3, 5] .
The conventional treatment of PMP is surgical debulking repeated, as necessary to alleviate pressure effects. However, this treatment is palliative. Repeated debulking surgeries become more and more difficult due to progressively thickened intra-abdominal adhesions [6] .
A combination of cytoreductive surgery(CRS) with hyperthermic intraoperative chemotherapy (HIPEC) was proposed by Sugarbaker. The rationale behind this strategy was to resect visible disease and any occult residual disease would be treated with a high concentration of chemotherapy and hyperthermia. [7 ] .
CRS/HIPEC era evolved in Lituania in 2011 [8] .
The aim of our study was to evaluate early-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in our University Hospital.
Material and methods
Patients with appendiceal tumors and peritoneal spread who underwent CRS/HIPEC from January 2012 to January 2016 were identified from a retrospectivelly collected database. No one patient did not receive any preoperative chemotherapy. Ronnett's histologic classification was used for tumor grading [3] . CT scan of the chest, abdomen, and pelvis and tumor markers (CEA, CA 19-9, and CA 125) were obtained prior to surgery. After review of the CT scan and the patient's functional status (ECOG = 0, 1, or 2), CRS/HIPEC was recommended if complete cytoreduction was deemed feasible. Prior surgery score (PSS) was assessed as previously described by Jacquet et al [6] . Excllusion criteria include patients with extra-abdominal metastases, patients deemed medically unfit to undergo radical surgery based on preoperative medical assessment, and those patients whose disease was considered technically unresectable at the multidisciplinary team meeting.
Under general anesthesia, a xypho-pubic incision was made. Disease extent was assesed, at the beginning and after CRS, by calculating peritoneal carcinomatosis index (PCI) as previously described by Jacquet et al [7] . All resections were done as needed to achieve complete cytoreduction, including excision of previous scar and port sites, anterior abdominal wall peritonectomy, splenectomy, cholecystectomy, greater and lesser omentectomy, diaphragmatic and pelvic peritonectomies, stripping of peritoneum over omental bursa and porta hepaticus, and visceral peritonectomies. We classified all peritonectomy procedures to nine peritonectomy regions described by Sugarbaker [7 ] . Disease-free peritoneum was not removed. Bowel and solid organs were removed, if disease could not be cleared. Every attempt was made to avoid stomas and extensive small bowel resections to help preserve quality of life. In our study we used sentinel lymph node concept to help decide if right colectomy is necessary with an appendiceal tumors [7 ] .
Complete cytoreduction (CC) was defined as no visible tumor nodules or nodules less than 2,5mm in size, using the CC score adopted by the consensus panel recommendations on peritoneal surface malignancies [7] . Following CRS, HIPEC was performed using a closed technique for 90 min before performing any anastomoses. For HIPEC we used Performer HT by Rand company. Mitomycin-C was used with a dose of 25 mg/m2; 10 mg given at time zero and 15 mg given 30 min later. The target outflow temperature was maintained at 41-42°C, which requires an iflow temperature of 42,5°. We were keeping 40-41C in pelvis and 40-41C in subdiaphragmatic space. Flow rate 1200ml/ min. . Urine output was maintained between 250 and 400 cc/h during perfusion to avoid renal toxicity.
Patients were maintained in the intensive care unit during the first 24 hours of the postoperative period or until stable, and then transferred to the surgical floor. Early mobilization was encouraged, with physical therapy assistance on postoperatie day 1. Low molecular weight heparin, compression stockings, and early mobilization were used for deep vein thrombosis prophylaxis. Patients were discharged when clinically stable; low molecular weight hepatin was continued on an outpatient basis for 21 days.
Results and discussions
From January 2012 to January 2016, 7 patients were treated for PMP from appendiceal origin in our institution; 6 of them were selected for our study following the criteria described above. One ,78 years old female patients was operated in our department . PCI was 36 and complete cytoreduction was not achieved. The major tumor debul-king was undertaken. She was not included in our study. Appendiceal origin was determined by histopathologic and immunoanalysis in all of our patients. Median age at diagnosis was 57 years (range, 39-67). All our patients were female. Five of them were operated by gynaecologists for Krukenberg tumor as primary surgery and one patient for acute perforated appendicitis.The previous surgery score (PSS) at the moment of admission was PSS-2 for three patients, PSS-3 for 3 patients. In five patients even one tumor marker was elevated. Four patients were diagnosed as DRAM and two as PMCA. Patient demographic, clinical and pathological data are summarized in table 1. A total of 6 patients underwent cytoreduction and peritonectomy plus HIPEC. In all of the patients, optimal cytoreduction CC-0 (5 patients) and CC-1 (one patient) was achieved. The median PCI score was 17 (range, 14-25) as an indicator of disease extension.The median number of visceral resections performed per patient was 3 (range, 1-5). (Table 2 ).
The median duration of CRS/HIPEC was 8 hours and 10 minutes (range, 7 hours and10 min. to 9 hours 20 min). Four patients received intraabdominal hypertermic chemotherapy, one patient -thoracoabdominal (after resection of diaphragm) and one patient (retroperitoneal PMP) retroperitoneal-peritoneal chemotherapy. Mean postoperative stay was 13 days (range, 8-18).One patient experienced temporary haemorhagic cystitis. The 30 days postoperative and in-hospital mortality were zero. Median follow-up time was 28 months (range, 8-45). (Table 3) .
At the time of analysis all patients are alive and without recurrence.
Discussion
Traditionally, debulking surgery was the standard treatment of PMP. Followed by multiple operations for successive recurrences. The short -term results of debulking surgery are excellent, but the disease is almost certain to recur after a short interval, requiring numerous operations, until the disease finally becomes inoperable [6 ] . CRS and HIPEC intraduced by Sugarbaker [7] has led to a marked improvement in survival rate compared with historical data, reaching differences in 5-years survival rates from 40% to 74% [6] .
Chua et al. evaluated outcome and long-term years) and the median progression-free survival rate was 98 months (8,2 years), with 10-and 15-year survival rates og 63% and 59 %, respectively. Multivariate analysis identified prior chemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001), major postoperative complications (P = .008), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreductions (CCR), 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer progression-free survival. Older age (P = .006), major postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemotherapy treatment (P = .001), and PMCA histopathologic subtype (P < .001) were independent predictors of a poorer overall survival. Reviewers concluded the combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years. Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve the outcome of this therapy to achieve long-term survival. Optimal cytoreduction achieves the best outcomes [10] . The aim of our study is to present our first experience of modern treatment of PMP of appendiceal origin in Klaipeda University Hospital.
Selecting patients for CRS/HIPEC remains challenging. Reviewing previous reports to establish guidelines for the selection is difficult partly because of the lack of consensus about pathology [4] . Ronnett's classification is the most widely used, but different classification systems have been suggested [9] . In addition, extent of disease is not reported in all studies. At our institution, we do not consider grade or extent of disease a contraindication to CRS/HIPEC. We make every effort to achieve CC, while minimizing visceral resection and preserving quality of life after surgery. These decisions are usually made intraoperatively. However, efforts for standardization of pathological reports are essential for future research and advancement in the treatment of this disease.
This study is a retrospective analysis with inherent limitations and relatively short mean follow-up and small number of patients. We did not deselect patients based solely on pathology type and tumor burden, and we closely monitor our patients postoperatively. To the best our our knowledge it the first report about surgical treatment of PMP in Lithuania.
Conclusions
PMP from appendiceal origin can be treated with curative intent in a large percentage of cases by cytoreductive surgery associated with HIPEC. This new approach could be performed safely with acceptable morbidity and mortality in selected patients treated in specialized centers.
